Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
The immune checkpoint inhibitor (ICI) ipilimumab has revolutionized the treatment of patients with different cancer histologies, including melanoma, renal cell carcinoma, and non-small cell lung carcinoma. However, only a subset of patients shows dramatic clinical responses to treatment. Despite int...
Main Authors: | Nicola J. Mason, Nicholas Chester, Ailian Xiong, Antonia Rotolo, Ying Wu, Sho Yoshimoto, Patrick Glassman, Gayathri Gulendran, Don L. Siegel |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2021.2004638 |
Similar Items
-
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
by: Sho Yoshimoto, et al.
Published: (2023-12-01) -
Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry in vitro
by: Sirintra Sirivisoot, et al.
Published: (2023-12-01) -
Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models
by: Yasuhiro Maruoka, et al.
Published: (2020-09-01) -
Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis
by: Cayman Williams, et al.
Published: (2022-08-01) -
A monoclonal antibody-based sandwich ELISA for measuring canine Thymidine kinase 1 protein and its role as biomarker in canine lymphoma
by: Hanan Sharif, et al.
Published: (2023-09-01)